Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Neuroprotective effects of increasing levels of HSP70 against neuroinflammation in Parkinson's disease model by inhibition of NF-κB and STAT3.
|
31408661 |
2019 |
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We concluded that, FR and Ex improved the motor performance in rotenone-induced PD rodent model which might be due to increased Hsp70 expression and TH density in corpus striatum and combination of both did not offer more protection than FR alone.
|
30113007 |
2019 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we report a novel hsp70-independent mechanism by which Hsp90 may also contribute to PD-associated neuropathology.
|
29471019 |
2018 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Heat-shock protein 70kDa (Hsp70) is involved in neuroprotection as a molecular chaperone in neurodegenerative disorders such as PD.
|
29107085 |
2018 |
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These findings demonstrated that Hsp70 was an important modulator in astrocytes induced inflammation, and up-regulation of Hsp70 might be a potential regulating approach for neuroinflammation-related neurodegenerative diseases, such as PD.
|
29183796 |
2018 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our findings support the therapeutic relevance of HSP70 induction for the prevention and/or deceleration of PD-like neurodegeneration.
|
29704482 |
2018 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here we investigate the factors controlling the intrinsic ability of human Hsp70 to inhibit the elongation of amyloid fibrils formed by the Parkinson's disease-related protein α-synuclein.
|
28230968 |
2017 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
HSP70 in particular prevents the aggregation of protein aggregation, such as α-synuclein, providing a degree of protection against PD.
|
26742515 |
2017 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Hsp70 regulates α-Synuclein (α-Syn) degeneration in Parkinson's disease (PD), indicating that Hsp70 promotion may be able to prevent or reverse α-Syn-induced toxicity in PD.
|
28810585 |
2017 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, Hsp70 is a well‑defined therapeutic target, and Hsp70 promotion is an efficient strategy to prevent or even reverse the α‑synuclein‑induced toxicity in PD.
|
26135068 |
2015 |
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These data confirm that overexpression of Hsp70 holds significant potential as a disease-modulating therapeutic approach for Parkinson's disease, with protective effects against early-onset α-synuclein-induced pathology demonstrated in the AAV-α-synuclein model.
|
24279716 |
2014 |
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Although familial PD is multifactorial in nature, a recent genetic screen involving PD patients identified two mitochondrial Hsp70 variants (P509S and R126W) that are suggested in PD pathogenesis.
|
22544056 |
2012 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
RGD |
Mildronate as a regulator of protein expression in a rat model of Parkinson's disease.
|
22186119 |
2011 |
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, we demonstrate that systemically applied Tat-Hsp70 effectively prevents neuronal cell death in in vitro and in vivo models of Parkinson's disease.
|
18182047 |
2008 |
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
HSP70 mRNA levels in mononuclear blood cells (MBCs) were compared in 14 CJD patients (10 confirmed by histo-pathological study), 12 vascular dementia (VD) patients, 16 patients with Parkinson's disease and dementia (PD) and 14 nondemented control subjects.
|
11200684 |
2000 |